Pearl River Capital’s Solid Biosciences SLDB Stock Holding History

Pearl River Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-78	Closed	-$10K	–	448
2019 Q1	$10K	Buy	+78	New	+$19.5K	0.02%	311

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Pearl River Capital's SLDB Position: Q2 2019 in Review

Pearl River Capital sold out of Solid Biosciences (SLDB) in Q2 2019, closing a stake of 78 shares — an estimated $10K sold.

Pearl River Capital first reported a position in SLDB in Q1 2019 and held it in 1 quarter. The position peaked at $10K in Q1 2019. 74 funds tracked by Wall St. Rank hold SLDB as of Q2 2019.

Pearl River Capital reported no remaining Solid Biosciences position as of Q2 2019 after selling out during the quarter.
Pearl River Capital sold 78 Solid Biosciences shares in Q2 2019, an estimated $10K.
Pearl River Capital first reported a position in Solid Biosciences in Q1 2019 and held it in 1 quarter.
Pearl River Capital's Solid Biosciences position peaked at $10K in Q1 2019.
74 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.